Company intelligence / Profile preview

US Biologic

Memphis, Tennessee, United States
Ownership
Private
Employees
~25
Development stage
Other
01

Overview

US Biologic has developed an orally delivered wildlife Lyme disease vaccine (Borrelia burgdorferi bacterin) that is integrated into the commercial LymeShield System for environmental Lyme control and is working with BARDA/DRIVe on an oral influenza vaccine and with USDA and DHS partners on multiple oral vaccines and antibiotic alternatives in animals; its programs are largely in pre-clinical and field-deployment stages rather than formal human clinical trial phases.

Therapeutic areas
Infectious Diseases
Modalities
VaccineDNA vaccineBiologic
Industry
Biotech
02

Drug pipeline

9 assets

oral influenza vaccine (US Biologic)

Preclinical

8 more assets in the full pipeline.

Request access →
03

Partnerships

U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVE)U.S. Department of Agriculture Agricultural Research Service (ARS)U.S. Department of Homeland Security Plum Island Animal Disease Center Science & Technology DirectorateUniversity of EdinburghJP McHale Pest Management (commercial LymeShield deployment partner)Global Lyme AllianceCenter for Lyme Action

Beyond the preview

Go deeper on US Biologic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on US Biologic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call